Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

BACKGROUND: Non–small-cell lung cancer (NSCLC) harboring the anaplastic lymphoma kinase gene (ALK) rearrangement is sensitive to the ALK inhibitor crizotinib, but resistance invariably develops. Ceritinib (LDK378) is a new ALK inhibitor that has shown greater antitumor potency than crizotinib in pre...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Shaw, Alice T., Kim, Dong-Wan, Mehra, Ranee, Tan, Daniel S.W., Felip, Enriqueta, Chow, Laura Q.M., Camidge, D. Ross, Vansteenkiste, Johan, Sharma, Sunil, De Pas, Tommaso, Riely, Gregory J., Solomon, Benjamin J., Wolf, Juergen, Thomas, Michael, Schuler, Martin, Liu, Geoffrey, Santoro, Armando, Lau, Yvonne Y., Goldwasser, Meredith, Boral, Anthony L., Engelman, Jeffrey A.
Formato: Artigo
Idioma:Inglês
Publicado em: 2014
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC4079055/
https://ncbi.nlm.nih.gov/pubmed/24670165
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1311107
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados